Temasek bags $793m from latest Celltrion sale

medical waste
By John Loh
23 Oct 2018

Temasek Holdings pocketed W902bn ($793m) from its second sell-down in South Korea’s Celltrion this year, after pricing it at the investor-friendly end of the range.

Bookrunners Credit Suisse and Citi marketed the shares at between W247,000 and W255,000 apiece, offering a discount of 5% to 8% to the biosimilar drugs manufacturer’s Monday close of W268,500.

Ion Investments, the vendor and a unit of Singapore sovereign wealth fund Temasek, had sold a block of shares ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial